Oncology · 2013 · 45 citations · 18 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMetastasisCancer ImmunotherapyMalignant NeoplasmsSquamous Cell CarcinomaTargeted TherapyToxicity ManagementCetuximab TherapyMetastatic Squamous Cell CarcinomaMulticenter TrialsPlatinum SensitivityPlatinum-based AgentsPlatinum-based CombinationsPlatinum-based RegimensRecurrent Metastatic Disease
BACKGROUND: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated in platinum-pretreated patients with recurrent and/or metastatic SCCHN. PATIENTS AND METHODS: A total of 84 patients were treated with docetaxel 35 mg/m(2) weekly for a maximum of 6 cycles and concomitant cetuximab 250 mg/m(2) weekly until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate and secondary endpoints included the response rate in relation to platinum sensitivity, progression-free survival (PFS), overall survival (OS) and toxicity. RESULTS: Nine (11%) patients achieved a partial response and 34 (40%) stable disease, resulting in a disease control rate of 51%. Response to treatment was 49% in previously platinum-sensitive and 50% in previously platinum-resistant disease. The median PFS was 3.1 months and the median OS 6.7 months. The most common grade 3 or 4 adverse events were mucositis (8%), pneumonia (8%), fatigue (8%) and skin reactions (14%). Sepsis occurred in 3 patients. CONCLUSION: Cetuximab plus docetaxel is an active treatment regimen with moderate toxicity in SCCHN patients. However, no superiority in comparison with monotherapy could be shown. Responsiveness and survival were independent of previous platinum sensitivity.
18
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Shiqing Li, Karl R. Schmitz, Philip D. Jeffrey et al. · Cancer Cell · 2005 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +13
Jan B. Vermorken, José Trigo, Ricardo Hitt et al. · Journal of Clinical Oncology · 2007 · 1K citations · Full text
Medicine, Oncology, Pharmacology +16
José Baselga, José Trigo, Jean Bourhis et al. · Journal of Clinical Oncology · 2005 · 491 citations
Medicine, Oncology, Chemotherapy +13